Observational Study to Determine the Incidence of New-Onset Valvulopathy in Patients Treated With Pergolide as Second-Line Therapy for Parkinson's Disease

Brief Summary

The primary objective of this study is to estimate the incidence of new-onset valvulopathy, determined by baseline and follow-up echocardiograms, in patients with Parkinson's Disease who are receiving pergolide as second-line therapy.

The secondary objective of the study is to estimate the prevalence of valvulopathy, as determined by baseline echocardiograms, among all patients who have Parkinson's Disease and are being considered for pergolide as second-line therapy.

Detailed Description

Not Provided

Study Type ICMJE

Observational

Study Design ICMJE

Observational Model: Defined PopulationTime Perspective: Longitudinal

Target Follow-Up Duration

Not Provided

Biospecimen

Not Provided

Sampling Method

Not Provided

Study Population

Not Provided

Condition ICMJE

Parkinson Disease

Intervention ICMJE

Not Provided

Study Group/Cohort (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ICMJE

Completed

Estimated Enrollment ICMJE

200

Completion Date

May 2007

Primary Completion Date

Not Provided

Eligibility Criteria ICMJE

Inclusion Criteria:

Male or female, age 18 and older with a diagnosis of Parkinson's Disease

Receiving pergolide as second-line therapy as prescribed by Summary of Product Characteristics

Willing to participate and sign a consent to release medical information

Have had an echocardiogram within 3 months of initiation of pergolide therapy with no evidence of cardiac valvulopathy

Exclusion Criteria:

There are no exclusion criteria for this study

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

No

Contacts ICMJE

Contact information is only displayed when the study is recruiting subjects